Mimedx (MDXG) Change in Acquisitions & Divestments (2014 - 2021)

Mimedx (MDXG) reported Change in Acquisitions & Divestments of $30000.0 for Q3 2021, little changed sequentially from $30000.0 in Q2 2021.

Mimedx (MDXG) Change in Acquisitions & Divestments (2014 - 2021) Analysis & Trends

Mimedx (MDXG) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $30000.0 in Q3 2021.

For the quarter ending Q3 2021, Change in Acquisitions & Divestments changed N/A year-over-year to $30000.0; the trailing twelve-month figure through Jun 2022 stood at $30000.0 (down 33.33% YoY), and the FY2021 full-year result was $75000.0, changed N/A from the prior year.
Change in Acquisitions & Divestments held at $30000.0 in Q3 2021, from $30000.0 in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $2.3 million in Q3 2019 to a low of $15000.0 in Q1 2021.
A 3-year average of $595833.3 and a median of $209500.0 in 2019 frame the typical range for Change in Acquisitions & Divestments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Mimedx	635.35 Mn	475.58 Mn	41.62 Mn

Download Data